Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeogenFRA:NG2 +1.32%68 Days Inventory is 118.09 as of May. 2026, which is 11% below its 10-year median of 132.78. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €9.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Neogen ranks better than 67.68% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Neogen's Average Total Inventories for the
three
months ended in May. 2026 was €130.2 Mil. Neogen's Cost of Goods Sold for the
three
months ended in May. 2026 was €100.6 Mil.
Hence, Neogen's Days Inventory for the
three
months ended in May. 2026 was 118.09.
The historical rank and industry rank for Neogen's Days Inventory or its related term are showing as below:
FRA:NG2'
s Days Inventory Range Over the Past 10 Years
Min: 112.23 Med: 132.78 Max: 148.91
Current: 134.8
During the past 13 years, Neogen's highest Days Inventory was 148.91. The lowest was 112.23. And the median was 132.78.
FRA:NG2's Days Inventory is ranked better than 67.68% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 176.445
vs FRA:NG2: 134.80
Neogen's Days Inventory
declined
from May. 2025 (142.16) to May. 2026 (118.09).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Neogen's Inventory Turnover for the
three
months ended in May. 2026 was 0.77.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Neogen's Inventory-to-Revenue for the
three
months ended in May. 2026 was 0.67.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Neogen's Inventory Turnover for the
three
months ended in May. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Neogen's Inventory to Revenue for the
three
months ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Neogen Days Inventory Related Terms
Neogen Days Inventory Historical Data
* Premium members only.
The historical data trend for Neogen's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs NVCR, AXGN, UFPT: Days Inventory Comparison
For the Medical Devices subindustry, Neogen's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Days Inventory distribution charts can be found below:
* The bar in red indicates where Neogen's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a Days Inventory of 118.09 as of May. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Neogen and its competitors. This is 11% below median its historical median of 132.78. Over the past decade, Neogen's Days Inventory has ranged from 112.23 to 148.91. According to the industry distribution chart, Neogen ranks #254 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 32.3%.
Is Neogen's Days Inventory too high?
Neogen's current Days Inventory of 118.09 is 11% below median its 10-year median of 132.78. Over the past 10 years, this metric has ranged from a low of 112.23 to a high of 148.91. The Medical Devices & Instruments industry median Days Inventory is 176.45. Neogen's value of 118.09 is 33.1% below this industry median. Based on the distribution chart, Neogen ranks #254 out of 786 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Neogen has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Days Inventory compare to NVCR and AXGN?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #254 out of 786 companies for Days Inventory. This puts Neogen in the upper half of its industry. The industry median Days Inventory is 176.45. Neogen's value of 118.09 is 33.1% below this benchmark. Historically, Neogen's own Days Inventory has ranged from 112.23 to 148.91 over the past decade. While the company's 10-year median is 132.78 vs. the industry median of 176.45, Neogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 176.45, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current Days Inventory of 118.09 is 33.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 176.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current Days Inventory is 118.09, which is 11% below median its own 10-year median of 132.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Fairly Valued. The stock's GF Value™ is €9.74, compared to a current price of €10.11 — trading 3.8% above its estimated fair value. The current Days Inventory is 118.09, which is 11% below median its 10-year median of 132.78 and 33.1% below the Medical Devices & Instruments industry median of 176.45. Neogen's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Days Inventory is 118.09 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be overvalued.
The current stock price of €10.11 is trading 3.8% above its estimated GF Value™ of €9.74.
GuruFocus considers Neogen to be Fairly Valued.
Key valuation signals for FRA:NG2:
Days Inventory: 118.09 (11% below median its 10-year median of 132.78)
GF Value™: €9.74 vs. price of €10.11 (3.8% above fair value)
Industry Position: 33.1% below the Medical Devices & Instruments median (#254 of 786)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
